Your session is about to expire
← Back to Search
Anti-PD-1 Therapy for Advanced Cancers
Study Summary
This trial is testing a new drug to see what dose is effective and how it works against different types of cancer.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2021 Phase 2 & 3 trial • 10 Patients • NCT03357952Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- My cancer can be measured or evaluated.I have been treated with drugs targeting PD-1, PD-L1, or PD-L2.I am a woman who can have children and my pregnancy test is negative.I do not have any severe ongoing illnesses that would interfere with the study.I am fully active or restricted in physically strenuous activity but can do light work.I can provide a recent tumor sample for study, either fresh or properly stored archival tissue.I haven't had cancer treatment or investigational drugs in the last 14 days to 28 days.I experienced severe side effects from past immunotherapy.I am not pregnant, breastfeeding, nor planning to become pregnant soon.
- Group 1: JNJ-63723283
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Does this research endeavor currently accept new volunteers?
"Clinicaltrials.gov shows that this experiment is currently recruiting participants, having been initially posted on the 21st of November 2016 and last modified on the 3rd of November 2022."
Has JNJ-63723283 been the focus of prior research?
"Presently, 8 research projects are underway exploring JNJ-63723283. One of them is currently in the third stage of clinical trials. The predominant site for this medication's experiments is Brasschaat, Quebec; however 1000 additional sites have joined to lend their aid."
What aims does this research endeavor aim to accomplish?
"The primary endpoint of this medical trial, which will be tracked for up to two years and six months, is the Average Concentration (Cavg) of JNJ-63723283. Secondary objectives consist of Ctrough, ORR per RECIST V1.1, as well as AEs observed in participants taking the medication."
How many participants are currently engaged in this experiment?
"Affirmative. Clinicaltrials.gov indicates that this clinical trial, which first appeared on November 21st 2016, is actively recruiting participants. 600 patients must be recruited from 1 medical site."
Is this the inaugural trial to investigate such a treatment?
"JNJ-63723283 has been undergoing clinical trials since 2016, when Janssen Research & Development, LLC sponsored the original trial with 600 participants. Following these successful Phase 1 and 2 studies, 8 live experiments are currently taking place in 35 countries across 92 cities."
Share this study with friends
Copy Link
Messenger